This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Winner

The drugs industry closed the day down 3%. Cardium Therapeutics Inc ( CXM), Natural Alternatives International ( NAII), Tekmira Pharmaceuticals Corporation ( TKMR), and Siga Technologies Inc ( SIGA) were all winners today within the drugs industry with Questcor Pharmaceuticals Inc ( QCOR) being today's featured drugs winner. Questcor Pharmaceuticals Inc rose $1.79 (7%) to $27.50 on heavy volume. Throughout the day, 2.2 million shares of Questcor Pharmaceuticals Inc exchanged hands as compared to its average daily volume of 1.4 million shares.

Questcor Pharmaceuticals, Inc., a pharmaceutical company, provides prescription drugs for central nervous system and inflammatory disorders. Its primary drug is H.P. Questcor Pharmaceuticals Inc has a market cap of $1.5 billion and is part of the health care sector. The company has a P/E ratio of 38.3, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 68.8% year to date as of the close of trading on Tuesday.

TheStreet Ratings rates Questcor as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

On the negative front, Ampio Pharmaceuticals Inc ( AMPE), Biodel Inc ( BIOD), Inhibitex Inc ( INHX), and Palatin Technologies Inc ( PTN) were all losers within the drugs industry with Valeant Pharmaceuticals International Inc ( VRX) being today's drugs industry Loser Spotlight stock.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs